Stockscreener 앱 받기
29.36
1.70%
0.49
시간 외 거래:
28.62
-0.74
-2.52%
전일 마감가:
$28.87
열려 있는:
$29.43
하루 거래량:
674.06K
Relative Volume:
0.54
시가총액:
$1.70B
수익:
$11.13M
순이익/손실:
$-105.04M
주가수익비율:
-13.01
EPS:
-2.2565
순현금흐름:
$-81.54M
1주 성능:
+9.06%
1개월 성능:
-16.76%
6개월 성능:
+465.70%
1년 성능:
+186.44%
1일 변동 폭
$28.85
$29.45
1주일 범위
$27.09
$30.00
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
29.36 | 1.67B | 11.13M | -105.04M | -81.54M | -2.2565 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Capricor drops following filing of lawsuit against Nippon Shinyaku - MSN
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
How Investors May Respond To Capricor Therapeutics (CAPR) Deramiocel Regulatory Uncertainty After Wider Q1 Loss - Sahm
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout
Capricor Therapeutics says NS Pharma delays could threaten access to Duchenne therapy - MSN
Should you sell your Capricor Therapeutics stock? - Cantech Letter
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot - TipRanks
CAPR stock sinks after-hours: Capricor launches legal fight over DMD therapy rollout ahead of FDA review - MSN
CAPRICOR (CAPR) CFO exercises stock options to acquire 3,000 shares - Stock Titan
10,000-share sale amendment for CAPR (NASDAQ: CAPR) - Stock Titan
CAPR (NASDAQ: CAPR) lists recent purchases and awards in Form 144 - Stock Titan
(CAPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection - MSN
Top 10 healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x - MSN
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Roth MKM Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $38 - Moomoo
CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy - TipRanks
Capricor Therapeutics, Inc. Q1 2026 earnings preview - MSN
Capricor (CAPR) Q1 2026 Earnings Transcript - AOL.com
Capricor Therapeutics (CAPR) director boosts stake via 3,937-share option exercise - Stock Titan
CAPR: Capricor Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
CAPRICOR THERAPEUTICS, INC. 1Q 2026: Revenue $9.4M, EPS ($0.59) — 10-Q Summary - TradingView
[10-Q] CAPRICOR THERAPEUTICS, INC. Quarterly Earnings Report - Stock Titan
CAPR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Capricor stock price target held at $63 by B.Riley on FDA progress - Investing.com UK
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2026 Earnings Call Transcript - Insider Monkey
Capricor Lawsuit Puts Duchenne Therapy Launch Plans And Valuation In Focus - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Q1 2026 Earnings Call Highlights: Strong Cash Position Amid Legal Challenges - GuruFocus
Capricor Therapeutics (CAPR) Provides Update on FDA Review and C - GuruFocus
Capricor Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Capricor Therapeutics Q1 Earnings Call Highlights - sharewise.com
Is Capricor Therapeutics (CAPR) Overvalued After Q1 2026 Update? - GuruFocus
Earnings call transcript: Capricor Therapeutics misses Q1 2026 EPS expectations - Investing.com India
Capricor Therapeutics: Runway Through 4Q27 >CAPR - Moomoo
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):